Login to Your Account

Idenix, GSK Team Up in $450M HIV Deal

By Catherine Hollingsworth

Monday, February 9, 2009
Idenix Pharmaceuticals Inc. has granted London-based GlaxoSmithKline plc worldwide rights to IDX899, a potential treatment for HIV/AIDS, in a deal that could bring in a potential $450 million for the U.S-based biotech. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription